Biomarkers and Disease Severity in Children With Community-Acquired Pneumonia.
Journal
Pediatrics
ISSN: 1098-4275
Titre abrégé: Pediatrics
Pays: United States
ID NLM: 0376422
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
accepted:
13
03
2020
pubmed:
15
5
2020
medline:
13
8
2020
entrez:
15
5
2020
Statut:
ppublish
Résumé
Host biomarkers predict disease severity in adults with community-acquired pneumonia (CAP). We evaluated the association of the white blood cell (WBC) count, absolute neutrophil count (ANC), C-reactive protein (CRP), and procalcitonin with the development of severe outcomes in children with CAP. We performed a prospective cohort study of children 3 months to 18 years of age with CAP in the emergency department. The primary outcome was disease severity: mild (discharged from the hospital), mild-moderate (hospitalized but not moderate-severe or severe), moderate-severe (eg, hospitalized with receipt of intravenous fluids, supplemental oxygen, complicated pneumonia), and severe (eg, intensive care, vasoactive infusions, chest drainage, severe sepsis). Outcomes were examined within the cohort with suspected CAP and in a subset with radiographic CAP. Of 477 children, there were no statistical differences in the median WBC count, ANC, CRP, or procalcitonin across severity categories. No biomarker had adequate discriminatory ability between severe and nonsevere disease (area under the curve [AUC]: 0.53-0.6 for suspected CAP and 0.59-0.64 for radiographic CAP). In analyses adjusted for age, antibiotic use, fever duration, and viral pathogen detection, CRP was associated with moderate-severe disease (odds ratio 1.12; 95% confidence interval, 1.0-1.25). CRP and procalcitonin revealed good discrimination of children with empyema requiring chest drainage (AUC: 0.83) and sepsis with vasoactive infusions (CRP AUC: 0.74; procalcitonin AUC: 0.78), although prevalence of these outcomes was low. WBC count, ANC, CRP, and procalcitonin are generally not useful to discriminate nonsevere from severe disease in children with CAP, although CRP and procalcitonin may have some utility in predicting the most severe outcomes.
Sections du résumé
BACKGROUND
Host biomarkers predict disease severity in adults with community-acquired pneumonia (CAP). We evaluated the association of the white blood cell (WBC) count, absolute neutrophil count (ANC), C-reactive protein (CRP), and procalcitonin with the development of severe outcomes in children with CAP.
METHODS
We performed a prospective cohort study of children 3 months to 18 years of age with CAP in the emergency department. The primary outcome was disease severity: mild (discharged from the hospital), mild-moderate (hospitalized but not moderate-severe or severe), moderate-severe (eg, hospitalized with receipt of intravenous fluids, supplemental oxygen, complicated pneumonia), and severe (eg, intensive care, vasoactive infusions, chest drainage, severe sepsis). Outcomes were examined within the cohort with suspected CAP and in a subset with radiographic CAP.
RESULTS
Of 477 children, there were no statistical differences in the median WBC count, ANC, CRP, or procalcitonin across severity categories. No biomarker had adequate discriminatory ability between severe and nonsevere disease (area under the curve [AUC]: 0.53-0.6 for suspected CAP and 0.59-0.64 for radiographic CAP). In analyses adjusted for age, antibiotic use, fever duration, and viral pathogen detection, CRP was associated with moderate-severe disease (odds ratio 1.12; 95% confidence interval, 1.0-1.25). CRP and procalcitonin revealed good discrimination of children with empyema requiring chest drainage (AUC: 0.83) and sepsis with vasoactive infusions (CRP AUC: 0.74; procalcitonin AUC: 0.78), although prevalence of these outcomes was low.
CONCLUSIONS
WBC count, ANC, CRP, and procalcitonin are generally not useful to discriminate nonsevere from severe disease in children with CAP, although CRP and procalcitonin may have some utility in predicting the most severe outcomes.
Identifiants
pubmed: 32404432
pii: peds.2019-3728
doi: 10.1542/peds.2019-3728
pmc: PMC7263054
pii:
doi:
Substances chimiques
Biomarkers
0
Calcitonin
9007-12-9
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : K01 AI125413
Pays : United States
Organisme : NIAID NIH HHS
ID : K23 AI121325
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR000078
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2020 by the American Academy of Pediatrics.
Déclaration de conflit d'intérêts
POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.
Références
Pediatr Infect Dis J. 2015 Aug;34(8):914-5
pubmed: 26020411
Eur J Clin Microbiol Infect Dis. 2012 May;31(5):825-33
pubmed: 21870054
Am J Emerg Med. 2012 Sep;30(7):1248-54
pubmed: 22030193
Ann Emerg Med. 2008 Jul;52(1):48-58.e2
pubmed: 18342993
Chest. 2004 Apr;125(4):1192-5
pubmed: 15078723
Am J Med. 2008 Mar;121(3):219-25
pubmed: 18328306
Respir Res. 2009 Jul 12;10:65
pubmed: 19594893
Eur Respir J. 2008 Feb;31(2):349-55
pubmed: 17959641
J Pediatric Infect Dis Soc. 2018 Feb 19;7(1):46-53
pubmed: 28158460
Eur Respir J. 2012 May;39(5):1144-55
pubmed: 22075489
Pediatrics. 2011 Aug;128(2):246-53
pubmed: 21746723
Pediatrics. 2016 Oct;138(4):
pubmed: 27688362
Arch Pediatr Adolesc Med. 2012 Dec;166(12):1155-64
pubmed: 23027409
N Engl J Med. 2015 Feb 26;372(9):835-45
pubmed: 25714161
Front Cell Infect Microbiol. 2018 Oct 30;8:382
pubmed: 30425971
Chest. 2005 Oct;128(4):2223-9
pubmed: 16236878
Clin Microbiol Infect. 2009 Nov;15(11):1026-32
pubmed: 19548923
J Clin Endocrinol Metab. 2004 Apr;89(4):1512-25
pubmed: 15070906
BMC Infect Dis. 2007 Mar 02;7:10
pubmed: 17335562
Acta Paediatr. 2007 Nov;96(11):1686-92
pubmed: 17888048
Clin Chem Lab Med. 2015 Mar;53(4):559-66
pubmed: 25014522
J Pediatr. 2015 Dec;167(6):1295-300.e4
pubmed: 26470685
Ann Thorac Med. 2014 Jul;9(3):162-7
pubmed: 24987476
Chest. 2016 Oct;150(4):819-828
pubmed: 27107491
Pediatrics. 2013 Aug;132(2):237-44
pubmed: 23878049
PLoS One. 2016 Nov 15;11(11):e0163262
pubmed: 27846213
Clin Biochem. 2016 Jan;49(1-2):47-50
pubmed: 26386341
Pediatr Infect Dis J. 2019 Sep;38(9):894-899
pubmed: 31232897
J Clin Epidemiol. 1996 Dec;49(12):1373-9
pubmed: 8970487
Scand J Infect Dis. 2007;39(2):129-37
pubmed: 17366029